Your browser doesn't support javascript.
loading
Optimizing lentiviral vector formulation conditions for efficient ex vivo transduction of primary human T cells in chimeric antigen receptor T-cell manufacturing.
Luostarinen, Annu; Kailaanmäki, Anssi; Turkki, Vesa; Köylijärvi, Marjut; Käyhty, Piia; Leinonen, Hanna; Albers-Skirdenko, Vita; Lipponen, Eevi; Ylä-Herttuala, Seppo; Kaartinen, Tanja; Lesch, Hanna P; Kekarainen, Tuija.
Afiliação
  • Luostarinen A; Advanced Cell Therapy Centre, Finnish Red Cross Blood Service, Helsinki, Finland. Electronic address: annu.luostarinen@bloodservice.fi.
  • Kailaanmäki A; Kuopio Center for Gene and Cell Therapy, Kuopio, Finland.
  • Turkki V; Kuopio Center for Gene and Cell Therapy, Kuopio, Finland.
  • Köylijärvi M; Kuopio Center for Gene and Cell Therapy, Kuopio, Finland.
  • Käyhty P; Kuopio Center for Gene and Cell Therapy, Kuopio, Finland.
  • Leinonen H; Kuopio Center for Gene and Cell Therapy, Kuopio, Finland.
  • Albers-Skirdenko V; Kuopio Center for Gene and Cell Therapy, Kuopio, Finland.
  • Lipponen E; Kuopio Center for Gene and Cell Therapy, Kuopio, Finland.
  • Ylä-Herttuala S; Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland.
  • Kaartinen T; Advanced Cell Therapy Centre, Finnish Red Cross Blood Service, Helsinki, Finland.
  • Lesch HP; Kuopio Center for Gene and Cell Therapy, Kuopio, Finland.
  • Kekarainen T; Kuopio Center for Gene and Cell Therapy, Kuopio, Finland.
Cytotherapy ; 26(9): 1084-1094, 2024 Sep.
Article em En | MEDLINE | ID: mdl-38661611
ABSTRACT
BACKGROUND

AIMS:

Chimeric antigen receptor (CAR) T-cell products are commonly generated using lentiviral vector (LV) transduction. Optimal final formulation buffer (FFB) supporting LV stability during cryostorage is crucial for cost-effective manufacturing.

METHODS:

To identify the ideal LV FFB composition for ex vivo CAR-T production, primary human T cells were transduced with vesicular stomatitis virus G-protein (VSV-G) -pseudotyped LVs (encoding a reporter gene or an anti-CD19-CAR). The formulations included phosphate-buffered saline (PBS), HEPES, or X-VIVOTM 15, and stabilizing excipients. The functional and viral particle titers and vector copy number were measured after LV cryopreservation and up to 24 h post-thaw incubation. CAR-Ts were produced with LVs in selected FFBs, and the resulting cells were characterized.

RESULTS:

Post-cryopreservation, HEPES-based FFBs provided higher LV functional titers than PBS and X-VIVOTM 15, and 10% trehalose-20 mM MgCl2 improved LV transduction efficiency in PBS and 50 mM HEPES. Thawed vectors remained stable at +4°C, while a ≤ 25% median decrease in the functional titer occurred during 24 h at room temperature. Tested excipients did not enhance LV post-thaw stability. CAR-Ts produced using LVs cryopreserved in 10% trehalose- or sucrose-20 mM MgCl2 in 50 mM HEPES showed comparable transduction rates, cell yield, viability, phenotype, and in vitro functionality.

CONCLUSION:

A buffer consisting of 10% trehalose-20 mM MgCl2 in 50 mM HEPES provided a feasible FFB to cryopreserve a VSV-G -pseudotyped LV for CAR-T-cell production. The LVs remained relatively stable for at least 24 h post-thaw, even at ambient temperatures. This study provides insights into process development, showing LV formulation data generated using the relevant target cell type for CAR-T-cell manufacturing.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transdução Genética / Linfócitos T / Lentivirus / Receptores de Antígenos Quiméricos / Vetores Genéticos Limite: Humans Idioma: En Revista: Cytotherapy Assunto da revista: TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transdução Genética / Linfócitos T / Lentivirus / Receptores de Antígenos Quiméricos / Vetores Genéticos Limite: Humans Idioma: En Revista: Cytotherapy Assunto da revista: TERAPEUTICA Ano de publicação: 2024 Tipo de documento: Article País de publicação: Reino Unido